Assessing Therapies

The researchers working on this particular project are conducting a molecular analysis of therapies for early and late stage prostate carcinoma. These investigations aim to determine molecular features that associate with response and resistance mechanisms to cytotoxic chemotherapy and pathway-targeted agents. Several clinical (translational) trials are underway including studies incorporating neoadjuvant therapies followed by radical prostatectomy. Tissue samples are acquired pre- and post-therapy and molecular correlates of direct drug effects are identified to define signatures: (a) predictive of therapeutic response and (b) predictive of disease outcome (relapse).